Commercialization of Nitroglycerin Ointment in the United States

Acrux Limited (ASX: ACR) announced the commercial launch of its Nitroglycerin Ointment, 0.4%, in the U.S. market, marking a significant milestone as its sixth FDA-approved Abbreviated New Drug Application since 2021. This product, a generic form of Rectiv, is specifically designed to treat moderate to severe pain associated with chronic anal fissures, addressing a crucial need in patient care. With the U.S. market for this treatment exceeding US$23 million annually, Acrux's generic is positioned to compete effectively against the branded product and another generic alternative.

This launch also represents Acrux's fourth successful commercialization in the U.S., showcasing its commitment to innovation and quality. With TruPharma, Acrux's licensee has initiated commercial activities and successfully manufactured the product. This achievement highlights Acrux's exceptional in-house research and development capabilities and reinforces its strategic focus on developing and commercializing topical products. Furthermore, commercial rights for this valuable product remain available in markets outside the United States, presenting exciting opportunities for growth and expansion.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com